<p>查爾斯·施瓦布信託公司在最近向證券交易委員會提交的 13F 表格中表示，在第三季度將其在雅培（NYSE:ABT - 免費報告）的持股增加了 109.8%。該公司在本季度購買了額外的 15,394 股後，持有 29,412 股這家醫療產品製造商的股票。根據其最近的 SEC 文件，查爾斯·施瓦布信託公司在雅培的持股價值為 3,939,000 美元。</p>
<p>獲取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>ABBV 股票：250 美元可能是大幅第三季度盈利超預期後的新底部</li>
</ul>
<p>其他大型投資者最近也增加或減少了對該公司的持股。IMG Wealth Management Inc.在第二季度將其在雅培的股份增加了 759.1%。IMG Wealth Management Inc.現在擁有 189 股這家醫療產品製造商的股票，價值 26,000 美元，此前在上個季度又購買了 167 股。Anfield Capital Management LLC 在第二季度將其在雅培的股份增加了 81.3%。Anfield Capital Management LLC 現在擁有 232 股這家醫療產品製造商的股票，價值 32,000 美元，此前在此期間又購買了 104 股。Delos Wealth Advisors LLC 在第二季度購買了雅培的新股份，價值 32,000 美元。Curio Wealth LLC 在第二季度將其在雅培的股份增加了 15,250.0%。Curio Wealth LLC 現在擁有 307 股這家醫療產品製造商的股票，價值 42,000 美元，此前在此期間又購買了 305 股。最後，Pineridge Advisors LLC 在第二季度將其在雅培的持股增加了 34.6%。Pineridge Advisors LLC 現在擁有 315 股這家醫療產品製造商的股票，價值 43,000 美元，此前在上個季度又購買了 81 股。目前，75.18% 的股票由機構投資者和對沖基金持有。</p>
<h2>分析師設定新目標價</h2>
<p>幾位股票分析師最近對該公司發佈了報告。加拿大皇家銀行在 10 月 16 日的研究報告中重申了 “跑贏大盤” 的評級，並將雅培的目標價設定為 147.00 美元。Weiss Ratings 在 12 月 15 日的研究報告中重新發布了對雅培的 “買入（b-）” 評級。瑞穗證券在 10 月 14 日的研究報告中將雅培的目標價從 135.00 美元上調至 140.00 美元，並給予該公司 “中性” 評級。雷蒙德·詹姆斯金融在 10 月 16 日的研究報告中將雅培的目標價從 141.00 美元上調至 146.00 美元，並給予該股票 “跑贏大盤” 評級。最後，Evercore ISI 在 10 月 15 日的研究報告中將雅培的目標價從 144.00 美元下調至 142.00 美元，併為該公司設定了 “跑贏大盤” 的評級。兩位股票研究分析師對該股票給予了強烈買入評級，十七位給予了買入評級，四位對該公司的股票給予了持有評級。根據 MarketBeat 的數據，雅培目前的平均評級為 “適度買入”，平均目標價為 147.00 美元。</p>
<ul>
<li>雅培十月股價暴跌是買入信號</li>
</ul>
<p><strong>查看我們對 ABT 的最新股票分析</strong></p>
<h2>雅培股票表現</h2>
<p>ABT 的股票在週五開盤價為 125.45 美元。該公司的速動比率為 1.24，流動比率為 1.70，債務與股本比率為 0.23。雅培的十二個月低點為 110.86 美元，十二個月高點為 141.23 美元。該股票的市值為 2181.3 億美元，市盈率為 15.72，市盈增長比率為 2.29，貝塔值為 0.72。該公司有 50 日移動平均線為 126.77 美元，200 日移動平均線為 130.24 美元。</p>
<ul>
<li>為什麼雅培是 2025 年第二季度的買入：增長與收益</li>
</ul>
<p>雅培（NYSE:ABT - 獲取免費報告）最近在 10 月 15 日宣佈了其財報。該醫療產品製造商報告本季度每股收益為 1.30 美元，符合市場共識預期的 1.30 美元。雅培的淨利潤率為 31.88%，股本回報率為 17.60%。該公司在本季度的收入為 113.7 億美元，而分析師預期為 114 億美元。在去年同期，該公司每股收益為 1.21 美元。該公司的收入同比增長了 6.9%。雅培已將其 2025 財年的每股收益指導設定為 5.120-5.180。作為一個整體，股票研究分析師預測雅培將在當前財年發佈 5.14 美元的每股收益。</p>
<h2>雅培增加股息</h2>
<p>該公司最近還宣佈了一項季度股息，將於 2 月 13 日（星期五）支付。1 月 15 日的登記投資者將獲得 0.63 美元的股息。這比雅培之前的季度股息 0.59 美元有所增加。這相當於每年 2.52 美元的股息，股息收益率為 2.0%。該股息的除息日期為 1 月 15 日（星期四）。雅培的股息支付比率（DPR）目前為 29.57%。</p>
<h2>關於雅培</h2>
<p>（免費報告）</p>
<p>雅培是一家全球醫療保健公司，總部位於伊利諾伊州的雅培公園，開發、製造和銷售廣泛的醫療產品和服務。雅培成立於 1888 年，通過多個業務領域運營，專注於診斷、醫療設備、營養品和成熟藥品。該公司向醫院、診所、實驗室、零售商和直接面向消費者的渠道提供旨在診斷、治療和管理各種健康狀況的產品。</p>
<p>在診斷方面，雅培提供實驗室和現場檢測平台及試劑，用於檢測傳染病、慢性病和生物標誌物；其 Alinity 系列儀器和快速檢測解決方案就是這一能力的例子。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票，勝過雅培</li>
<li>在投資中，下調評級意味着什麼？</li>
<li>這三家銀行在年末前上漲，但這種趨勢會持續嗎？</li>
<li>現在值得購買的三隻巨型成長股</li>
<li>這三隻飆升的股票剛剛獲得標準普爾 500 指數的最終認可</li>
<li>什麼是成長股及其投資</li>
<li>這隻 ETF 在美聯儲降息後獲得了重大助力</li>
</ul>
<p><strong>想看看其他對雅培持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取雅培（NYSE:ABT - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在雅培嗎？</h2>
<p>在考慮雅培之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛的市場注意到之前立即購買的股票……而雅培並不在名單上。</p>
<p>雖然雅培目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

雅培

嘉信理財

<p>查爾斯·施瓦布信託公司在第三季度將其在雅培的持股增加了 109.8%，目前擁有 29,412 股，價值 394 萬美元。這一舉動是機構投資者調整在雅培股份的更廣泛趨勢的一部分。分析師對雅培設定了適度買入評級，目標價格為 147.00 美元。雅培最近的財報符合預期，淨利潤率為 31.88%，收入同比增長 6.9%</p>

<p>Charles Schwab Trust Co increased its position in Abbott Laboratories (NYSE:ABT - Free Report) by 109.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm owned 29,412 shares of the healthcare product maker's stock after purchasing an additional 15,394 shares during the quarter. Charles Schwab Trust Co's holdings in Abbott Laboratories were worth $3,939,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>查爾斯·施瓦布信託公司在最近向證券交易委員會提交的 13F 表格中表示，在第三季度將其在雅培（NYSE:ABT - 免費報告）的持股增加了 109.8%。該公司在本季度購買了額外的 15,394 股後，持有 29,412 股這家醫療產品製造商的股票。根據其最近的 SEC 文件，查爾斯·施瓦布信託公司在雅培的持股價值為 3,939,000 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>ABBV 股票：250 美元可能是大幅第三季度盈利超預期後的新底部</li>
</ul>
</div><p>Other large investors also recently added to or reduced their stakes in the company. IMG Wealth Management Inc. raised its stake in shares of Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker's stock worth $26,000 after buying an additional 167 shares during the last quarter. Anfield Capital Management LLC lifted its stake in shares of Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker's stock valued at $32,000 after purchasing an additional 104 shares during the period. Delos Wealth Advisors LLC bought a new position in shares of Abbott Laboratories in the 2nd quarter worth $32,000. Curio Wealth LLC grew its stake in shares of Abbott Laboratories by 15,250.0% during the second quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker's stock worth $42,000 after purchasing an additional 305 shares during the period. Finally, Pineridge Advisors LLC increased its holdings in Abbott Laboratories by 34.6% in the second quarter. Pineridge Advisors LLC now owns 315 shares of the healthcare product maker's stock valued at $43,000 after purchasing an additional 81 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他大型投資者最近也增加或減少了對該公司的持股。IMG Wealth Management Inc.在第二季度將其在雅培的股份增加了 759.1%。IMG Wealth Management Inc.現在擁有 189 股這家醫療產品製造商的股票，價值 26,000 美元，此前在上個季度又購買了 167 股。Anfield Capital Management LLC 在第二季度將其在雅培的股份增加了 81.3%。Anfield Capital Management LLC 現在擁有 232 股這家醫療產品製造商的股票，價值 32,000 美元，此前在此期間又購買了 104 股。Delos Wealth Advisors LLC 在第二季度購買了雅培的新股份，價值 32,000 美元。Curio Wealth LLC 在第二季度將其在雅培的股份增加了 15,250.0%。Curio Wealth LLC 現在擁有 307 股這家醫療產品製造商的股票，價值 42,000 美元，此前在此期間又購買了 305 股。最後，Pineridge Advisors LLC 在第二季度將其在雅培的持股增加了 34.6%。Pineridge Advisors LLC 現在擁有 315 股這家醫療產品製造商的股票，價值 43,000 美元，此前在上個季度又購買了 81 股。目前，75.18% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>Several equities analysts have recently issued reports on the company. Royal Bank Of Canada restated an &#34;outperform&#34; rating and set a $147.00 target price on shares of Abbott Laboratories in a research report on Thursday, October 16th. Weiss Ratings reissued a &#34;buy (b-)&#34; rating on shares of Abbott Laboratories in a research note on Monday, December 15th. Mizuho upped their target price on shares of Abbott Laboratories from $135.00 to $140.00 and gave the company a &#34;neutral&#34; rating in a research note on Tuesday, October 14th. Raymond James Financial lifted their price target on shares of Abbott Laboratories from $141.00 to $146.00 and gave the stock an &#34;outperform&#34; rating in a research report on Thursday, October 16th. Finally, Evercore ISI lowered their price objective on shares of Abbott Laboratories from $144.00 to $142.00 and set an &#34;outperform&#34; rating for the company in a research report on Wednesday, October 15th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, Abbott Laboratories currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $147.00.</p>
<div class="lb-trans"><p>幾位股票分析師最近對該公司發佈了報告。加拿大皇家銀行在 10 月 16 日的研究報告中重申了 “跑贏大盤” 的評級，並將雅培的目標價設定為 147.00 美元。Weiss Ratings 在 12 月 15 日的研究報告中重新發布了對雅培的 “買入（b-）” 評級。瑞穗證券在 10 月 14 日的研究報告中將雅培的目標價從 135.00 美元上調至 140.00 美元，並給予該公司 “中性” 評級。雷蒙德·詹姆斯金融在 10 月 16 日的研究報告中將雅培的目標價從 141.00 美元上調至 146.00 美元，並給予該股票 “跑贏大盤” 評級。最後，Evercore ISI 在 10 月 15 日的研究報告中將雅培的目標價從 144.00 美元下調至 142.00 美元，併為該公司設定了 “跑贏大盤” 的評級。兩位股票研究分析師對該股票給予了強烈買入評級，十七位給予了買入評級，四位對該公司的股票給予了持有評級。根據 MarketBeat 的數據，雅培目前的平均評級為 “適度買入”，平均目標價為 147.00 美元。</p>
</div><ul>
<li>Abbott Laboratories' October Price Plunge Is a Signal to Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培十月股價暴跌是買入信號</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Analysis on ABT</strong></p>
<div class="lb-trans"><p><strong>查看我們對 ABT 的最新股票分析</strong></p>
</div><h2>Abbott Laboratories Price Performance</h2>
<div class="lb-trans"><h2>雅培股票表現</h2>
</div><p>Shares of ABT opened at $125.45 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The stock has a market capitalization of $218.13 billion, a P/E ratio of 15.72, a P/E/G ratio of 2.29 and a beta of 0.72. The company has a 50 day moving average of $126.77 and a 200-day moving average of $130.24.</p>
<div class="lb-trans"><p>ABT 的股票在週五開盤價為 125.45 美元。該公司的速動比率為 1.24，流動比率為 1.70，債務與股本比率為 0.23。雅培的十二個月低點為 110.86 美元，十二個月高點為 141.23 美元。該股票的市值為 2181.3 億美元，市盈率為 15.72，市盈增長比率為 2.29，貝塔值為 0.72。該公司有 50 日移動平均線為 126.77 美元，200 日移動平均線為 130.24 美元。</p>
</div><ul>
<li>Why Abbott Laboratories Is a Q2 2025 Buy: Growth &amp; Yield</li>
</ul>
<div class="lb-trans"><ul>
<li>為什麼雅培是 2025 年第二季度的買入：增長與收益</li>
</ul>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 EPS for the quarter, hitting the consensus estimate of $1.30. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. The business had revenue of $11.37 billion during the quarter, compared to analysts' expectations of $11.40 billion. During the same quarter in the prior year, the company posted $1.21 earnings per share. The firm's revenue was up 6.9% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 獲取免費報告）最近在 10 月 15 日宣佈了其財報。該醫療產品製造商報告本季度每股收益為 1.30 美元，符合市場共識預期的 1.30 美元。雅培的淨利潤率為 31.88%，股本回報率為 17.60%。該公司在本季度的收入為 113.7 億美元，而分析師預期為 114 億美元。在去年同期，該公司每股收益為 1.21 美元。該公司的收入同比增長了 6.9%。雅培已將其 2025 財年的每股收益指導設定為 5.120-5.180。作為一個整體，股票研究分析師預測雅培將在當前財年發佈 5.14 美元的每股收益。</p>
</div><h2>Abbott Laboratories Increases Dividend</h2>
<div class="lb-trans"><h2>雅培增加股息</h2>
</div><p>The business also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be given a $0.63 dividend. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.59. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Thursday, January 15th. Abbott Laboratories's dividend payout ratio (DPR) is presently 29.57%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項季度股息，將於 2 月 13 日（星期五）支付。1 月 15 日的登記投資者將獲得 0.63 美元的股息。這比雅培之前的季度股息 0.59 美元有所增加。這相當於每年 2.52 美元的股息，股息收益率為 2.0%。該股息的除息日期為 1 月 15 日（星期四）。雅培的股息支付比率（DPR）目前為 29.57%。</p>
</div><h2>About Abbott Laboratories</h2>
<div class="lb-trans"><h2>關於雅培</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.</p>
<div class="lb-trans"><p>雅培是一家全球醫療保健公司，總部位於伊利諾伊州的雅培公園，開發、製造和銷售廣泛的醫療產品和服務。雅培成立於 1888 年，通過多個業務領域運營，專注於診斷、醫療設備、營養品和成熟藥品。該公司向醫院、診所、實驗室、零售商和直接面向消費者的渠道提供旨在診斷、治療和管理各種健康狀況的產品。</p>
</div><p>In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.</p>
<div class="lb-trans"><p>在診斷方面，雅培提供實驗室和現場檢測平台及試劑，用於檢測傳染病、慢性病和生物標誌物；其 Alinity 系列儀器和快速檢測解決方案就是這一能力的例子。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>What Does Downgrade Mean in Investing?</li>
<li>These 3 Banks Are Rallying Into Year-End, But Will It Continue?</li>
<li>3 Monster Growth Stocks to Buy Now</li>
<li>3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&amp;P 500</li>
<li>What Are Growth Stocks and Investing in Them</li>
<li>This ETF Caught a Major Tailwind After the Fed’s Rate Cut</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過雅培</li>
<li>在投資中，下調評級意味着什麼？</li>
<li>這三家銀行在年末前上漲，但這種趨勢會持續嗎？</li>
<li>現在值得購買的三隻巨型成長股</li>
<li>這三隻飆升的股票剛剛獲得標準普爾 500 指數的最終認可</li>
<li>什麼是成長股及其投資</li>
<li>這隻 ETF 在美聯儲降息後獲得了重大助力</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對雅培持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取雅培（NYSE:ABT - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在雅培嗎？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮雅培之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛的市場注意到之前立即購買的股票……而雅培並不在名單上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然雅培目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

嘉信理財信託公司持有雅培 394 萬美元的股票